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Abstract
With multiple genome-wide association studies (GWAS) performed across autoimmune diseases, there is a great
opportunity to study the homogeneity of genetic architectures across autoimmune disease. Previous approaches have been
limited in the scope of their analysis and have failed to properly incorporate the direction of allele-specific disease
associations for SNPs. In this work, we refine the notion of a genetic variation profile for a given disease to capture strength
of association with multiple SNPs in an allele-specific fashion. We apply this method to compare genetic variation profiles of
six autoimmune diseases: multiple sclerosis (MS), ankylosing spondylitis (AS), autoimmune thyroid disease (ATD),
rheumatoid arthritis (RA), Crohn’s disease (CD), and type 1 diabetes (T1D), as well as five non-autoimmune diseases. We
quantify pair-wise relationships between these diseases and find two broad clusters of autoimmune disease where SNPs
that make an individual susceptible to one class of autoimmune disease also protect from diseases in the other autoimmune
class. We find that RA and AS form one such class, and MS and ATD another. We identify specific SNPs and genes with
opposite risk profiles for these two classes. We furthermore explore individual SNPs that play an important role in defining
similarities and differences between disease pairs. We present a novel, systematic, cross-platform approach to identify allele-
specific relationships between disease pairs based on genetic variation as well as the individual SNPs which drive the
relationships. While recognizing similarities between diseases might lead to identifying novel treatment options, detecting
differences between diseases previously thought to be similar may point to key novel disease-specific genes and pathways.
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Introduction
Autoimmune diseases share many genetic factors resulting in
similarity of disease mechanisms. For instance the HLA region is
known to be associated with several autoimmune diseases
including T1D, MS, RA as well as others [1,2]. Certain
autoimmune diseases, such as MS and ATD [3], T1D and celiac
disease [4] commonly co-occur in patients [5,6]. Classes of drugs,
for instance steroids, are known to treat groups of inflammatory
and autoimmune conditions such as RA, CD, MS and systemic
lupus erythematosus.
Despite these similarities, there is evidence that points towards
genetic differences between autoimmune diseases. For instance
rs2076530 (A/G), a single nucleotide polymorphism (SNP) in
BTNL2 (butyrophilin-like 2, a MHC class II associated gene), has
been shown to be strongly associated with several autoimmune
diseases such as MS, RA, T1D, sarcoidosis and systemic lupus
erythematosus (SLE) [7–12]. A more in depth analysis shows that
while the G allele of the polymorphism was more frequent among
patients with T1D and RA than healthy controls, the A allele was
more frequent in patients with SLE than in healthy individuals
[12]. This example demonstrates the idea that while a single SNP
might be significantly associated with several disorders, an allele
could make an individual susceptible to one disease, but be
protective of another. Finally we know that despite the common
mechanisms of autoimmune diseases, there are drugs that treat
one autoimmune condition, but unexpectedly worsen another. For
instance infliximab, an anti-TNF agent, has been demonstrated to
offer benefits for the treatment of some autoimmune disorders,
such as RA and AS [13,14], but it fails or even exacerbates the
condition in patients with other disorders such as MS [15].
Similarly interferon-beta, which is widely used to treat MS, has no
effect on RA patients [16].
With multiple genome-wide association studies (GWAS) per-
formed across autoimmune diseases, we have an ideal setup to
study the homogeneity of genetic architectures across autoimmune
disease. By sampling specific locations in the genome, the
technology behind GWAS allows us to quickly and accurately
analyze samples for genetic variations that contribute to disease
predisposition. Since being introduced in 2007, GWAS have
helped identify several hundred common marker alleles that are
associated with over seventy different conditions [17]. Integrative
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study a single disease of interest such as type II diabetes [18].
Genome-wide association (GWA) data has also been integrated
with gene expression data to prioritize genes for disease association
[19].
In this work, we define a novel concept of a disease variation
profile and carry out comparative analyses to find similarities and
differences in the genetic architectures of common diseases.
Studying genetic variation in autoimmune diseases in particular
allows us to systematically define a disease classification based on
allele-specific relationships. We find individual polymorphisms
where the same alleles are significantly associated with multiple
autoimmune conditions as well as polymorphisms where different
alleles are significantly associated with multiple conditions.
Several measures of association are commonly used to quantify
the relationship between a SNP and a disease phenotype. A p-
value measures how much evidence there is against the hypothesis
that the allele distribution in the control and disease populations is
the same. An odds-ratio is the ratio of the probability that a disease
individual has a certain allele to the probability of a healthy
control having that allele. An odds-ratio of 1 implies that the allele
is equally likely in both groups. An odds-ratio greater than one
implies that the allele is more likely in the disease group. Similarly,
an odds-ratio less than one implies that the allele is less likely in the
disease group. While the odds-ratio doesn’t reflect the sample size
of the study, the width of the confidence interval on the odds-ratio
is reflective of sample size. The odds-ratio furthermore allows us to
specify which allele is associated with the disease and how strong
that association is.
Recent studies explored the genetic relationships between seven
common diseases studied by Wellcome Trust Case Control
Consortium (WTCCC) [20] based on similarities of associated
genes and their pathways [21–23]. Previous approaches use p-
values to measure the significance of the association between a
SNP and a single disease from genome-wide association data, and
compute a measure of similarity between these p-values in pairs of
diseases. While these approaches are able to identify pairs of
diseases that have similar genetic variation profiles based purely on
strength of association of each loci, the metric is not allele-specific,
meaning it does not distinguish between which of the two alleles is
associated with a disease. In our own previous work, we have used
a classifier approach in order to discover similarities in disease
variation profiles [24] by examining a large number of SNPs for
each individual instead of analyzing the significance of individual
SNPs across diseases. While successful in finding similarities
between diseases, the classifier approach requires individual
genotype data to be carried out on the same platform.
In this paper, we present a novel, allele-specific, cross-platform
method for comparing genetic architecture of disease for which
GWA data is available. Our approach relies on the raw summary
statistics of genome-wide association studies and does not require
obtaining individual level genotype data. As a result, our approach
allows for data to be combined across different platforms. We
define a genetic variation score (GVS) for each SNP-disease pair as
a combination of the p-value to represent the strength of
association between the SNP and the disease phenotype and the
odds-ratio to specify which allele is the one associated with the
disease (see Methods). We define a genetic variation profile for a
disease as a vector of the GVS values across all the measured
SNPs. We use the genetic variation profiles to discover allele-
specific relationships between disease pairs.
We apply our method to a combined dataset of two WTCCC
[20,25] studies to uncover positive and negative disease relation-
ships within six autoimmune diseases, multiple sclerosis (MS),
ankylosing spondylitis (AS), autoimmune thyroid disease (ATD),
rheumatoid arthritis (RA), Crohn’s disease (CD), and type 1
diabetes (T1D), and five non-autoimmune diseases, bipolar
disorder (BD), coronary artery disease (CAD), hypertension
(HT), type 2 diabetes (T2D), and breast cancer (BC). Applying
our method to this broad panel, we expected to find all the known
autoimmune diseases clustered similarly. However, we find two
separate classes of autoimmune disease. RA and AS fall into one
class, while MS and ATD into the other. T1D is similar to ATD,
but not MS and therefore is difficult to classify. CD is similar to
none of the other five autoimmune diseases and thus is not further
discussed with the other autoimmune diseases. We identify specific
SNPs and genes with similar and opposite risk profiles for these
two classes of autoimmune disease and suggest differing mecha-
nisms of disease and strategies for future drug development for the
two classes.
Results
In this work, we analyze genome-wide association data across a
set of eleven conditions to find allele-specific similarities and
differences across disease. Our combined dataset includes six
autoimmune diseases (MS, AS, ATD, RA, CA and T1D) and five
non autoimmune diseases (BC, BD, CAD, HT and T2D). We
added independent GWA studies for two autoimmune diseases:
RA from North American Rheumatoid Arthritis Consortium
(NARAC) and the Swedish Epidemiological Investigation of
Rheumatoid Arthritis (EIRA) [26] and MS from the International
Multiple Sclerosis Genetics Consortium (IMSGC) [27]. In order to
be able to compare genetic variation profiles across eleven diseases
on different platforms, we only consider 573 SNPs that are
commonly measured in these datasets (see Methods). The
distribution of these SNPs throughout the genome (Figure S1)
does not exhibit a visible bias. We furthermore carry out several
experiments in order to assess the validity of using a small subset of
SNPs to obtain our findings (see Discussion).
By examining the strength of association of each SNP with each
disease (p-value), we found a set of SNPs which are significantly
associated with all 5 autoimmune diseases in our dataset (Table 1).
Author Summary
In this work, we define a novel concept of a disease
variation profile and carry out comparative analyses to find
similarities and differences in the genetic architectures of
common diseases. Studying genetic variation across
autoimmune disease in particular allows us to systemat-
ically identify allele-specific relationships. We find poly-
morphisms where the alleles are significantly similarly
associated with multiple autoimmune conditions as well as
polymorphisms where alleles are significantly differentially
associated with multiple conditions. We apply this method
to compare genetic variation profiles of six autoimmune
diseases: multiple sclerosis (MS), ankylosing spondylitis
(AS), autoimmune thyroid disease (ATD), rheumatoid
arthritis (RA), Crohn’s disease (CD), and type 1 diabetes
(T1D), as well as five non-autoimmune diseases. We find
two autoimmune disease groups where SNPs that make an
individual susceptible to one class of autoimmune disease
also protect from diseases in the other autoimmune class.
As more genome-wide association data becomes available,
future studies could be done across tens or hundreds of
diseases yielding the commonalities and differences in
genetic architectures across all of human disease.
Inverse Allelic Association in Autoimmune Diseases
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that individual alleles are oppositely associated with different
autoimmune diseases. Our analysis supports the fact that simple
consideration of p-values as a genetic variation profile of a
disease is not sufficiently representative of the potential disease
mechanisms.
For each disease-SNP pair, we define a new genetic variation
score (GVS) by combining both the uncorrected p-value to capture
the strength of association, and the odds-ratio, to account for
which allele is associated with a given disease (see Methods). For
each disease, a genetic variation profile consists of GVS for all the
SNPs commonly measured across our input GWAS. We use
Pearson correlation to measure allele-specific similarities and
differences between disease pairs. In order to test the significance
of our findings, we compute the false discovery rate (FDR) for the
correlations by comparing the actual distribution of correlations to
that calculated on a randomized dataset (see Methods). To identify
relationships between groups of diseases, hierarchical cluster
analysis is applied to the data using the computed Pearson
correlation coefficients as a distance metric between disease pairs.
In order to confirm our findings, we included additional
independent studies of RA and MS in our analysis [26,27].
The comparison between genetic variation profiles of 11
diseases is shown in Figure 1 (Table S1) with the corresponding
FDR (Table S2). We can see that there are two main groupings of
autoimmune diseases, with T1D showing similarity to both
groupings, and CD to neither. Although CD is an inflammatory
disease affecting the gastrointestinal tract with an autoimmune
component, as we did not see a strong relationship between CD
and the other set of autoimmune diseases in our analysis, we did
not consider it with the rest of the autoimmune diseases in our
further discussion. We also notice that the non-autoimmune
diseases are clustered together. HT, BD, T2D, CAD and BC are
all slightly positively correlated. One implication of the positive
correlations between these diseases is that there might be a
common underlying genetic variation profile of disease. While we
are interested in exploring this notion in the future, we focus our
discussion here on the stronger and more surprising relationships
between autoimmune diseases that we find.
Both RA datasets and AS have similar genetic variation profiles
(Pearson correlation 0.340 and 0.357) and are negatively
correlated with genetic variation profiles of both MS datasets
and ATD (Pearson correlation 20.42 and 20.353). Out of 573
SNPs that are commonly measured in all the datasets, we find a set
of nine SNPs such that one allele predisposes an individual to one
class of autoimmune diseases, but protects from the other class
(Table 2). When a similar analysis was carried out on randomized
null data, over 100 trials, on average less than a single SNP is
found using the same criteria. While this relationship has been
previously established for rs2076530 in BTNL2 in a subset of the
autoimmune diseases [12], we systematically identify all such SNPs
which are significantly associated with at least one disease per class
(Table 2). Some of these regions have previously been associated
with autoimmunity; for example rs10484565 falls in a gene called
TAP2, which encodes a membrane-associated protein that is a
member superfamily of ATP-binding cassette (ABC) transporters.
While mutations in this gene have been previously associated with
ankylosing spondylitis, insulin-dependent diabetes mellitus, and
Grave’s Disease [28–30], the inverse allelic relationship has not
been previously recognized. rs1265048 falls near CDSN and
PSORS1C1 both of which have previously been associated with
susceptibility to psoriasis [31,32]. rs151719 falls in HLA-DMB,a n
MHC class II molecule that has been previously associated with
T1D [33]. We hypothesize that there are loci which pre-dispose
individuals to autoimmune disease in general (such as rs1132200 in
TMEM39A in Table 1) and other loci that determine which class
or more specifically which autoimmune disease an individual is
more likely to get (Table 2).
In discovering these two classes of autoimmune disease, we find
positive and negative pair-wise relationships between genetic
Table 1. SNPs significantly associated with RA, AS, T1D, MS, and ATD (p,0.05).
SNP - Allele Gene Symbol Sign of the Odds-Ratio | P-value
RA AS T1D ATD MS
rs1063635 – A LOC100129668 2 6.01E-08 + 1.83E-59 2 8.65E-10 2 8.30E-03 2 9.27E-05
rs1132200 – A TMEM39A 2 2.24E-02 2 1.77E-02 2 8.28E-03 2 4.02E-03 2 4.56E-03
rs1634717 – A 2 1.80E-04 + 6.00E-13 + 4.94E-14 + 1.68E-06 + 3.34E-03
rs204991 – C GPSM3 2 3.67E-08 2 9.34E-13 + 9.40E-24 + 5.04E-11 2 1.70E-03
rs2076530 – G BTNL2 + 3.50E-57 + 8.76E-15 + 2.64E-14 2 3.93E-07 2 3.00E-19
rs2242655 – C C6orf47 + 1.21E-03 + 5.75E-23 + 1.53E-05 2 1.13E-02 2 7.42E-05
rs2248462 – A 2 1.33E-03 + 1.09E-99 2 5.00E-25 2 1.45E-05 2 5.94E-19
rs2299851 – T MSH5 + 4.91E-02 + 1.10E-22 + 1.04E-04 2 4.69E-02 2 5.52E-06
rs2517646 – G TRIM10 2 1.98E-04 2 2.29E-03 2 1.86E-06 2 1.26E-02 + 7.59E-06
rs2844463 – T BAT3 2 6.40E-07 2 1.56E-04 + 1.47E-05 2 1.15E-02 + 3.70E-02
rs3129953 – T BTNL2 2 2.54E-11 2 2.13E-09 + 1.47E-40 + 2.66E-15 2 4.18E-05
rs3135363 – C 2 5.69E-22 2 7.21E-04 + 9.81E-12 + 4.46E-15 2 5.11E-07
rs4428528 – C 2 1.01E-18 2 2.19E-03 + 8.16E-23 + 7.11E-12 2 1.22E-03
rs887464 – A PSORS1C3 + 3.20E-03 + 7.89E-09 + 7.43E-28 + 2.03E-05 2 7.28E-10
rs9267954 – T + 2.89E-38 + 3.27E-13 + 4.40E-12 2 2.50E-02 2 2.17E-14
SNPs that are significantly associated with all five autoimmune diseases (based on p-values previously reported by the WTCCC). While these SNPs are commonly
significantly associated with five autoimmune diseases in our dataset, by examining the signs of the odds-ratios we see that for the same SNP, often different alleles are
associated with different diseases.
doi:10.1371/journal.pgen.1000792.t001
Inverse Allelic Association in Autoimmune Diseases
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disease pairings that are significantly correlated (FDR,0.01) from
our dataset: NARAC RA and ATD (Pearson correlation 20.433),
WTCCC RA and ATD (Pearson correlation 20.353), NARAC
RA and WTCCC MS (Pearson correlation 20.367), WTCCC RA
and WTCCC MS (Pearson correlation 20.42), AS and WTCCC
MS (Pearson correlation 20.322), AS and IMSGC MS (Pearson
correlation 20.256), WTCCC MS and T1D (Pearson correlation
20.229), T1D and ATD (Pearson correlation 0.49), WTCCC RA
and NARAC RA (Pearson correlation 0.935), and WTCCC MS
and IMSGC MS (Pearson correlation 0.717) (Table S1, highlight-
ed in red).
Figure 1. Disease heatmap based on genetic variation profiles. This diagram shows correlations between disease genetic variation profiles.
Positive relationships between a pair of diseases are shown in brown, negative relationships are shown in purple. The diseases highlighted in blue
have an autoimmune component. Hierarchical clustering using these correlations as a distance metric is shown on the left. Approximately Unbiased
(AU) probability values (%) for each cluster indicating how strongly the cluster is supported by data are shown in red. Clusters with AU larger than
95% are strongly supported by data.
doi:10.1371/journal.pgen.1000792.g001
Table 2. SNPs with opposite risk profiles in two autoimmune classes.
SNP - Allele Gene Symbol Genetic Variation Score (GVS)
RA (NARAC) RA AS T1D ATD MS (IMSGC) MS
rs11752919 - C ZSCAN23 23.48 23.21 29.39 1.10 0.70 3.25 2.99
rs3130981 - A CDSN 20.46 21.00 29.47 24.94 0.33 10.00 13.41
rs151719 - G HLA-DMB 26.71 24.77 21.08 213.63 0.34 8.58 17.76
rs10484565 - T TAP2 25.52 8.37 1.34 15.74 21.36 20.56 20.30
rs1264303 - G VARS2 11.51 7.36 18.76 0.89 21.76 21.85 21.75
rs1265048 - C CDSN 6.59 2.97 50.13 6.34 20.85 22.39 24.16
rs2071286 - A NOTCH4 5.30 0.78 6.42 4.04 20.03 21.89 22.45
rs2076530 - G BTNL2 67.49 56.46 14.06 13.58 26.41 29.50 218.52
rs757262 - T TRIM40 14.58 9.11 6.27 1.56 20.79 22.05 27.34
SNPs such that one allele predisposes an individual to one class of autoimmune diseases (RA and AS), but protects from the other class (MS and ATD) or vice versa. Each
SNP in this set has a significant association (p,0.05) with at least one disease per class. The SNPs where the minor allele has a negative odds-ratio (protective) are
underlined to show the separation more clearly.
doi:10.1371/journal.pgen.1000792.t002
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A negative correlation between two genetic variation profiles
means that while the two phenotypes have strong association with
the same SNPs, alleles are oppositely responsible for predisposing
an individual to each of the diseases. Therefore if two phenotypes
have negatively correlated genetic variation profiles, some alleles
that are susceptible to one phenotype are protective of the other
and vice versa.
The strongest negatively correlated disease pair is ATD and the
NARAC RA study with a correlation score of 20.433. This
finding is supported by a strong negative correlation between ATD
and the WTCCC RA genetic variation profiles (Pearson
correlation 20.353). The average lowest negative correlation on
randomized data from 100 trials was 20.13 with a standard
deviation 0.09. RA is a chronic, systemic autoimmune disorder in
which the immune system attacks the joints, causing joint
inflammation and destruction. ATD, also referred to as Grave’s
Disease, is caused by an antibody-mediated autoimmune reaction
resulting in neck swelling, bulging eyes and hyperthyroidism.
There is a known association between rheumatologic and thyroid
disorders [34]. Early studies of autoimmune thyroid disease and
thyroid auto-antibodies in rheumatoid arthritis patients suggest
that there may be a common genetic link between RA and
autoimmune thyroid disease [35,36]. More recently it has been
suggested that the abnormalities of the joints and thyroid gland are
related most probably due to a genetic predisposition determined
by the affiliation to a certain HLA type, most often HLA-DR
[37–39]. We find a set of SNPs which are strongly associated with
both ATD and RA but when we look at the allele-specific
genotype counts for these loci, we see that while one of the alleles is
more common in RA patients, the other is more common in ATD
patients. The negative association trend between WTCCC RA
and ATD and the individual SNPs contributing to the correlation
are shown in Figure 2. Those include polymorphisms in
complement factor B (CFB), nuclear envelope membrane protein
(NRM), heat shock protein (HSPA1B) as well as others. Similarly,
the significant negative association trend between NARAC RA
and ATD is shown in Figure S2.
Multiple sclerosis (WTCCC) and rheumatoid arthritis (WTCCC)
are significantly negatively correlated (Pearson correlation 20.42,
Figure 3). This finding is supported by a significant negative
correlation between NARAC RA and the WTCCC MS genetic
variation profiles (Pearson correlation 20.367, Figure S3) as well as
a weaker negative correlations between WTCCC RA and IMGSC
MS as well as NARAC RA and IMSGC MS genetic variation
profiles (Pearson correlations 20.204 and 20.141 respectively).
Multiple sclerosis is an autoimmune condition in which the immune
system attacks the myelin sheaths of the central nervous system. We
have not been able to find any recorded co-occurrence of the two
disorders from previous research. With the exception of the HLA
region there has beenvery little worklinking genetic susceptibility of
these two immunological disorders. We identify a set of SNPs for
which an allele predisposes an individual to RA while being
protective of MS and vice versa. The negative association trend
between RA and MS and the individual SNPs contributing to the
correlation are shown in Figure 3. Those include polymorphisms in
HLA-B associated transcript 3 (BAT3), E74-like factor 1 (ELF1),
HLA-DMB, VARS2, BTNL2, TRIM40, ZSCAN23 and CDSN.
Similarly, the genetic variation profiles of AS and WTCCC MS
are negatively correlated (Pearson correlation 20.322, Figure 4).
Figure 2. Genetic Variation Scores for RA (WTCCC) and ATD. Genetic Variation Scores (GVS) for SNPs that are significantly associated with
both diseases (p,0.05) are shown in black. The non-significant GVS are shown in gray. The best fit linear model of the data is shown in red.
doi:10.1371/journal.pgen.1000792.g002
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between AS and the IMSGC MS genetic variation profiles
(Pearson Correlation -0.256, Figure S4). Ankylosing spondylitis is a
systemic rheumatic disease resulting in chronic inflammation of
the spine and the sacroiliac joints. Several individual loci have
been linked to both disorders but overall association has not been
previously established. For instance, while association of the IL23R
gene with inflammatory bowel disease, psoriasis and ankylosing
spondylitis [25] has been shown before, only recently has its
involvement also been linked to MS [40]. We identify a set of
SNPs for which one allele predisposes an individual to AS while
being protective of MS, and vice versa. These include polymor-
phisms in mediator of DNA-damage checkpoint 1 (MDC1), HLA-
B associated transcript 2 (BAT2), as well as others.
Positive Disease–Disease Relationships
A positive correlation between two genetic variation profiles
means that not only the same SNPs, but also the same alleles lead
an individual to be more susceptible to both phenotypes.
The highest non-obvious positive correlation of 0.481 is
between T1D and ATD. The average highest positive correlation
on randomized data from 100 trials was 0.12 with a standard
deviation 0.08. The positive association trend as well as individual
data points can be seen on Figure 5. T1D is an autoimmune
disease that results in destruction of insulin-producing beta cells of
the pancreas. Several recent studies reported shared variants
among these autoimmune disorders [41,42]. There is increasing
evidence that autoimmune thyroid disease is frequent in patients
with T1D [43,44]. Co-occurrence of T1D and ATD in the same
patient or family has also been studied from the epidemiological
perspective resulting in finding several common susceptibility
genes [45]. Two loci that have previously been reported to be
associated with T1D were recently shown to also be significant risk
factors for the co-occurrence of ATD and T1D in Japanese
individuals [46]. We identify over a dozen other loci, mostly in the
HLA region, which are commonly associated between the two
diseases.
The overall strongest positive correlations, as expected, are
those between the two RA (WTCCC and NARAC) and the two
MS (WTCCC and IMSGC) datasets (Pearson correlation
coefficients of 0.935 and 0.717 respectively), which confirms our
hypothesis. Figures S5 and Figure S6 show the strong positive
correlation between the genetic variation profiles of the two RA
and MS studies respectively. This result supports the proposed
design for a disease-specific genetic variation profile and the
comparison metric used in the analysis.
Discussion
In this work, we present a novel notion of a genetic variation
profile and apply it to carry out comparative analysis of a set of
eleven diseases. Half of these diseases are known to have an
autoimmune component including RA, T1D, AS, MS and ATD.
Our analysis yields several significant positive and negative
relationships between these diseases. We identify two broader
classes of autoimmune disease (RA and AS fall into one, and MS
and ATD into the other) as well as a set of SNPs which when
predisposing an individual to one class of the diseases protects
from the second. We explore individual SNPs and genes that play
an important role in defining similarities and differences between
disease pairs.
Figure 3. Genetic Variation Scores for RA (WTCCC) and MS (WTCCC). Genetic Variation Scores (GVS) for SNPs that are significantly associated
with both diseases (p,0.05) are shown in black. The non-significant GVS are shown in gray. The best fit linear model of the data is shown in red.
doi:10.1371/journal.pgen.1000792.g003
Inverse Allelic Association in Autoimmune Diseases
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capture which allele is susceptible and which is protective and are
thus not a good metric for studying similarities and differences in
disease genetic variation profiles. We introduce a novel notion of a
genetic variation score (GVS) which captures both the strength of
association of a given SNP and whether an allele is protective or
susceptible. Using this measure we are able to identify new positive
and negative relationships between disease pairs as well as identify
individual SNPs which drive the relationships such as previously
reported rs2076530 in BTNL2, in which the G allele predisposes to
RA, AS and T1D, but protects from MS and ATD [12].
We have shown that studying genetic variation across
autoimmune diseases in particular allows us to systematically
identify allele-specific pleiotropic effects. We find that the same
allele can be associated with multiple phenotypes. A likely
explanation for the same SNP allele being associated with different
phenotypes is that it interacts differentially with genetic and
environmental factors that change the biological context of the
SNP in different individuals. More importantly, we find that
certain alleles can be disease-associated in one setting and disease-
protective in another. We hypothesize that there are some loci
which pre-dispose individuals to disease in general, and other loci
that determine which class or more specifically which disease an
individual is more likely to get.
More specifically, we find that certain MHC polymorphisms
predispose individuals to one class of autoimmune disease but are
protective against the other (Table 2). We hypothesize that this
could be due to their involvement in peptide-MHC loading. For
instance HLA-DM (rs151719), a chaperone binder for nascent
MHC molecules, could differentially modulate peptide binding
and thus antigen presentation. TAP2 (rs10484565) is also involved
in transporting peptides from the cytoplasm to the ER to couple
them with nascent MHC molecules. Both HLA-DM and TAP2 are
involved in peptide-MHC loading, which could explain their
diametric effects. These MHC chaperone binders might load
pathogenic peptides for one disease but not another. CDSN
(rs1265048) is also located in the MHC on chromosome 6, but has
not been described to alter antigen presentation.
Phenotypic expression of variant alleles is influenced differen-
tially by environment, stochastic events, and interactions with
multiple other genetic loci. Traditional SNP analysis does not
account for gene interactions, however gene interactions are
instrumental for understanding principles for how, when and why
genetic variation is phenotypically expressed [47]. We show in this
report that genetic variants are expressed differentially, with
respect to human disease, presumably due to the combined action
of different alleles of several genes. However, the molecular basis
of such gene interactions remains only speculative [48]. Pheno-
typic expression depends on the environmental and genetic
context of a biological system. Borrowing from the literature in
microbial systems biology, these can be viewed as constraints on
the biological system in question [49]. The environmental and
genetic constraints of one disease may be highly inconsistent with
another. Though they share a common SNP, the particular allele
may act as an ‘on switch’ or alternatively an ’off’ switch in making
an individual more or less susceptible to disease.
Classification of diseases based on allelic differences may be
used in the future to illuminate potential new therapies. Certain
drugs like anti-TNF have positive effects in RA, psoriasis and
ankylosing spondylitis as compared to MS suggesting that certain
Figure 4. Genetic Variation Scores for AS and MS (WTCCC). Genetic Variation Scores (GVS) for SNPs that are significantly associated with both
diseases (p,0.05) are shown in black. The non-significant GVS are shown in gray. The best fit linear model of the data is shown in red.
doi:10.1371/journal.pgen.1000792.g004
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Assuming specific alleles of genes that are useful for classifying
diseases reflect an underlying biological process, then it follows
that drugs useful for treating any particular disease may be useful
for treating another disease in its class. Thus, integration of clinical
correlates with genomic sub-classification of diseases could be a
useful and relatively straightforward strategy for personalized
medicine.
There are a few limitations to our current approach that should
be recognized. The data for the analysis is obtained from several
types of arrays. While our approach allows for data analysis across
multiple platforms, it is dependent on the intersection of coverage
between all those platforms. The overlap coverage in terms of
SNPs between all platforms that we currently analyze is minimal
(573 SNPs). A larger overlap could be obtained by using linkage
disequilibrium and taking advantage of SNPs in the same
haplotype blocks or by applying imputation techniques, but we
chose to rely solely on the data available to us, until confidence in
imputation methods improves. In addition while our current
approach relies solely on the summary statistics data, introducing
an imputation step in our pipeline would require us to obtain and
incorporate individual genotype data, which we see as a drawback.
In order to assess the validity of using a small subset of SNPs to
obtain our findings, we repeated the experiment considering only
the diseases (RA, HT, T1D, T2D, CAD, CD and BD) for which
the genotyping was done using Affymetrix GeneChip 500K
Mapping Array Set across nearly 500,000 measured SNPs. This
allowed us to compute similarities between genetic variation
profiles using all the SNPs on the array. We find that the pair-wise
correlations resulting from this analysis are very similar to those
obtained using only the 573 overlapping SNPs (Pearson correla-
tion 0.88). This also holds for the diseases (MS, AS, ATD and BC)
genotyped using the custom Illumina Infinium array across nearly
15,000 measured SNPs (Pearson correlation 0.98). Therefore we
show that the pair-wise disease correlations that we compute using
the common subset of 573 SNPs can be extrapolated to a genome-
wide scale to draw conclusions regarding disease classification.
The overlap problem will improve as more data on more common
platforms becomes available in the future, and as more individuals
are tested using whole genome sequencing. We also acknowledge
that there are other more sophisticated statistical methods to
compare genetic architectures and to cluster genetic variation
profiles, however we picked a simple parsimonious approach to
test our hypothesis.
In conclusion, we present a novel, systematic, cross-platform
methodology to identify allele-specific relationships between
disease pairs based on genetic variation as well as the individual
SNPs which drive the relationships. We apply this method to
compare genetic variation profiles of eleven diseases across several
independent studies. We find two autoimmune disease groups
where SNP alleles that make an individual susceptible to one class
of autoimmune disease also protect from diseases in the other
autoimmune class. Further integration of different types of
biomedical data will improve our ability to conjure biological
explanations for findings from GWAS. For instance, correlating
genetic variation to gene expression might help interpret the
molecular and genetic complexity of human disease [51]. As more
GWA data becomes available, our method could be applied across
tens or hundreds of diseases yielding the commonalities and
differences in genetic architectures across all of human disease.
Figure 5. Genetic Variation Scores for ATD and T1D. Genetic Variation Scores (GVS) for SNPs that are significantly associated with both
diseases (p,0.05) are shown in black. The non-significant GVS are shown in gray. The best fit linear model of the data is shown in red.
doi:10.1371/journal.pgen.1000792.g005
Inverse Allelic Association in Autoimmune Diseases
PLoS Genetics | www.plosgenetics.org 8 December 2009 | Volume 5 | Issue 12 | e1000792Methods
The data for our analysis was obtained from two separate
Wellcome Trust Case Control Consortium (WTCCC) studies: a
GWA study of 2,000 cases and 3,000 shared controls for 7
complex human diseases (BD, CAD, CD, HT, RA, T1D and
T2D) carried out with the Affymetrix GeneChip 500K Mapping
Array Set, which comprises 500,568 SNPs and an association
study of 1,500 common controls 1,000 cases for each of BC, ATD,
AS, and MS carried out with a custom-made Illumina Infinium
array with 14,436 non-synonymous SNPs. We introduce a second
rheumatoid arthritis (1522 cases and 1850 controls) [26] as well as
another multiple sclerosis (931 cases and 2431 controls) [27] GWA
datasets to our analysis to further support our findings. The
rheumatoid arthritis study combines data from North American
Rheumatoid Arthritis Consortium (NARAC) and the Swedish
Epidemiological Investigation of Rheumatoid Arthritis (EIRA) to
genotype 317,503 SNPs using several versions of Illumina
Infinium BeadChips. 297,086 SNPs that passed filters in both
the NARAC and EIRA sample collections were merged into a
single dataset for analysis. The MS study, carried out by the
International Multiple Sclerosis Genetics Consortium (IMSGC)
examined a set of 334,923 SNPs using Affymetrix GeneChip 500K
Mapping Array Set.
We used the pre-computed p-values from the above experi-
ments in our analysis. The smaller and larger WTCCC studies
used the snpMatrix [52] and the PLINK [53] programs
respectively to calculate a p-value for the strength of association
between a SNP and a disease. For the independent RA analysis
PLINK program [53] was used to carry out Cochran-Mantel-
Haenszel stratified analysis and for the independent MS analysis
transmission disequilibrium test was applied using the Whole-
genome Association Study Pipeline (WASP) as well as PLINK
[53]. The odds-ratios were re-computed using the genotype counts
provided in the summary statistics for each experiment.
We start out by finding the SNPs common to both experiments.
Each SNP is mapped to Entrez GeneID and corresponding gene
symbol by querying dbSNP. SNPs that do not fall within a gene
are not assigned one. The intersection of the two WTCCC studies
as well as the two additional GWA datasets results in a set of 573
SNPs, which we use for our analysis. The distribution of these
SNPs in the genome is shown in Figure S1. We confirm that each
of the studies integrated in the pipeline have the data encoding on
the same DNA strand by keeping track which allele was measured
and comparing the counts of individuals with each measured allele
for the control populations. For each SNP we consider the disease
associations with respect to the minor allele. Please note that in
some studies, the major allele is actually the risk allele therefore
what we refer to as risk and protective may be different from the
published studies of these phenotypes.
We define the notion of a genetic variation profile as a
combination of log-odds scores and p-values for each SNP
measuring allele-specific association between the SNP and each
of the eleven diseases in the combined dataset. Using p-values
alone as proposed previously by Torkamani et al. [21] does not
capture which allele is associated with a given disease, as shown in
Table 1. Log odds-ratios alone do not account for significance of
association due to sample size. A typical relationship between log
odds-ratios and log p-values are shown by a volcano plot (see
Figure S7). The alleles for which the log odds-ratio is negative
signify that the allele tested is less likely to appear in a disease
individual (left half of the plot). The alleles for which the log odds-
ratio is positive signify that the allele tested is more likely to appear
in a disease individual (right half of the plot). From a volcano plot
we can also see that p-values and odds-ratios are not necessarily
correlated. One can envision a situation where a rare allele has a
high magnitude odds-ratio with respect to a disease phenotype, but
a poor p-value. These values fall into the lower corners of a
volcano plot (Figure S7). Similarly, if the sample size is very large,
a SNP that has a small effect might have a significant p-value, but
an odds-ratio close to 1. Such values would fall into the top center
of a volcano plot (Figure S7). A combination of p-values and odds-
ratios is needed in order to capture the strength and direction of
association between a SNP and a disease. Therefore we propose
combining these two measures of association to represent a disease
genetic variation profile. More specifically for each disease d and
SNP s, we define a genetic variation score GVS[d,s] where d
(number of diseases)=1…n and s (number of SNPs)=1…m:
GVS[d,s]=sign(log(odds-ratio[d,s]))*(log(p-value[d,s])).
With respect to the minor allele, an odds-ratio greater than one
implies that the minor allele is more likely in the disease group. An
odds-ratio less than one implies that the minor allele is less likely in
the disease group, which means that the major allele is more likely
in the disease group. Therefore by looking at the sign of the log of
the odds-ratio we can specify which allele is the one associated
with a disease. We capture the significance and strength of that
association by multiplying the sign of the log of the odds-ratio by
the log of the p-value. After computing the GVS for each disease-
SNP pair, we define a genetic variation profile for each disease as a
vector of the GVS for all the measured SNPs. This allows us to
capture strength of disease association across multiple SNPs in an
allele-specific fashion.
As a similarity metric between diseases, we compute the Pearson
correlation between disease-specific genetic variation profiles.
Pearson correlation, ranging from 21t o+1, reflects the strength
of a linear relationship between two variables. The correlation
coefficient is positive between two diseases if the GVS for both
diseases tend to be simultaneously greater than, or simultaneously
less than, their respective means. The correlation coefficient is
negative if GVS for a pair of diseases tend to lie on opposite sides of
their respective means. Although other approaches might be
considered more robust to outliers, the method we choose to apply
relies on the actual GVS scores as opposed to a ranked ordering of
them. Since GVS scores directly reflect the strength of association
between SNPs and disease, computing a similarity metric on the
rank ordering of GVS would result in information loss. Multiple
hypothesis testing was not applied to the p-values prior to the
calculation of GVS to keep our methodology simple, since scaling
the p-values by a constant amount (such as inBonferronicorrection)
would not change our calculated correlation coefficients.
In order to measure significance of the computed correlation
coefficients, we re-compute the correlations on randomized data
and compute a false discovery rate (FDR) for each actual
correlation. Specifically we create the randomized distribution
by shuffling SNP labels for each disease and re-compute the pair-
wise Pearson correlations between the disease profiles. The
randomization is carried out 100 times. The density plot
comparison between the actual distribution of correlation
coefficients and the ones generated from randomized data are
shown in Figure S8.
When computing the false discovery rates, we consider the
positive and the negative correlations separately. For each actual
correlation score, we count the fraction of top correlations from all
randomizations which are at least as extreme as the one we are
examining. The false discovery rates based on the randomized
distribution are reported in Table S2. We conservatively consider
a correlation between two disease profiles to be significant at a
false discovery rate of 0.01.
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applied to the data using the computed Pearson correlation
coefficients as a distance metric between disease pairs. Initially,
each disease is assigned to its own cluster. The algorithm proceeds
iteratively, at each stage joining the two most similar clusters, until
there is just a single cluster left. We use the Pvclust R package [54]
to compute a bootstrap analysis of the clusters. The bootstrap
probability of a cluster corresponds to the frequency with which
the cluster appears in bootstrap samples of the data. Approxi-
mately Unbiased (AU) probability values are computed using
bootstrap samples of various sizes and indicate how strongly the
cluster is supported by data (AU.95%).
Supporting Information
Figure S1 Distribution of Commonly Measured SNPs. The
distribution of the genomic locations of 573 SNPs that are
commonly measured across all the datasets we examine for our
analysis.
Found at: doi:10.1371/journal.pgen.1000792.s001 (0.17 MB PDF)
Figure S2 Genetic Variation Scores for RA (NARAC) and ATD
Datasets. Genetic Variation Scores (GVS) for SNPs that are
significantly associated with both datasets (p,0.05) are shown in
black. The non-significant GVS are shown in gray. The best fit
linear regression model of the data is shown in red.
Found at: doi:10.1371/journal.pgen.1000792.s002 (0.56 MB PDF)
Figure S3 Genetic Variation Scores for RA (NARAC) and MS
(WTCCC) Datasets. Genetic Variation Scores (GVS) for SNPs
that are significantly associated with both datasets (p,0.05) are
shown in black. The non-significant GVS are shown in gray. The
best fit linear regression model of the data is shown in red.
Found at: doi:10.1371/journal.pgen.1000792.s003 (0.64 MB PDF)
Figure S4 Genetic Variation Scores for MS (IMSGC) and AS
Datasets. Genetic Variation Scores (GVS) for SNPs that are
significantly associated with both datasets (p,0.05) are shown in
black. The non-significant GVS are shown in gray. The best fit
linear regression model of the data is shown in red.
Found at: doi:10.1371/journal.pgen.1000792.s004 (0.56 MB PDF)
Figure S5 Genetic Variation Scores for WTCCC and IMSGC
MS Datasets. Genetic Variation Scores (GVS) for SNPs that are
significantly associated with both datasets (p,0.05) are shown in
black. The non-significant GVS are shown in gray. The best fit
linear regression model of the data is shown in red.
Found at: doi:10.1371/journal.pgen.1000792.s005 (0.68 MB PDF)
Figure S6 Genetic Variation Scores for WTCCC and NARAC
RA Datasets. Genetic Variation Scores (GVS) for SNPs that are
significantly associated with both datasets (p,0.05) are shown in
black. The non-significant GVS are shown in gray. The best fit
linear model of the data is shown in red.
Found at: doi:10.1371/journal.pgen.1000792.s006 (0.70 MB PDF)
Figure S7 Volcano Plot (log-odds vs. log p-values) for RA
(WTCCC). This plot shows the typical relationship between log-
odds ratios and log p-values for an association study. There is no
clear relationship between the two measures, meaning that a SNP
with a good log-odds ratio, might have a non-significant p-
value and a SNP with a significant p-value might have a small
odds-ratio.
Found at: doi:10.1371/journal.pgen.1000792.s007 (0.18 MB PDF)
Figure S8 Randomization based on Genetic Variation. Distri-
bution of correlation scores between pairs of diseases. The
distribution based on actual data is shown in red. The distribution
of correlations based on randomized data is shown in blue. These
are used to compute the false discovery rate for individual pair-
wise disease correlations which are presented in Table S2.
Found at: doi:10.1371/journal.pgen.1000792.s008 (0.16 MB PDF)
Table S1 Pair-wise disease correlations based on Disease
Genetic Variation profiles. Values shown in red indicate FDR
less than or equal to 0.01.
Found at: doi:10.1371/journal.pgen.1000792.s009 (0.05 MB
DOC)
Table S2 False discovery rates (FDR) based on randomized
data. Values shown in red indicate FDR less than or equal to 0.01.
Found at: doi:10.1371/journal.pgen.1000792.s010 (0.04 MB
DOC)
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